Episurf Medical Q4: Setting the stage for 2025 - Redeye

Redeye provides an in-depth review of Episurf Medical’s Q4 report and events during and after the quarter. The report contained no major surprises; however, we are encouraged by the progression in the current FDA clearance process relating to Episealer MTP and the new distribution agreement with Joint Operations Ltd.

Länk till analysen i sin helhet: https://www.redeye.se/research/1072841/episurf-medical-q4-setting-the-stage-for-2025?utm_source=finwire&utm_medium=RSS